

Accepted Manuscript

Acute convexity subarachnoid hemorrhage: what the neurosurgeon needs to know


I.C. Hostettler, MD, D.J. Werring, FRCP PhD

PII: S1878-8750(18)32885-7

DOI: <https://doi.org/10.1016/j.wneu.2018.12.062>

Reference: WNEU 11008

To appear in: *World Neurosurgery*



Please cite this article as: Hostettler I, Werring D, Acute convexity subarachnoid hemorrhage: what the neurosurgeon needs to know, *World Neurosurgery* (2019), doi: <https://doi.org/10.1016/j.wneu.2018.12.062>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Acute convexity subarachnoid hemorrhage: what the neurosurgeon needs to know

IC Hostettler MD¹, DJ Werring FRCP PhD¹

¹ *Stroke Research Centre, University College London, Institute of Neurology, London, UK*

Corresponding author: Professor David Werring, FRCP, PhD

UCL Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, Russell Square House, 10 - 12 Russell Square, London WC1B 5EH, UK.

Tel: +44 (0)20 3108 7493; Fax: +44 (0)20 7833 8613; Email: d.werring@ucl.ac.uk

Keywords

Non-traumatic convexity/convexial/cortical subarachnoid hemorrhage, cerebral amyloid angiopathy, intracerebral hemorrhage, ischemic stroke, cortical superficial siderosis, stroke

When faced with a nontraumatic subarachnoid hemorrhage (SAH), neurosurgeons typically search for the commonest cause: a ruptured aneurysm. However, an increasingly recognized and differential diagnosis is acute convexity subarachnoid hemorrhage (cSAH). In cSAH – which accounts for about 6% of all nontraumatic SAH¹- bleeding is limited to the subarachnoid space over the convexities of the brain and not extending into the sylvian fissures, parenchyma, ventricles, or basal cisterns,² a pattern readily distinguished from the more diffuse pattern seen in aneurysmal SAH. The two commonest causes of cSAH typically affect different age groups and cause characteristic syndromes. In older patients (>60 years) the commonest cause is cerebral amyloid angiopathy (CAA), presenting with transient focal neurological symptoms (TFNE) of unilateral spreading sensory or motor symptoms^{3,4} attributed to cortical irritation from the overlying acute hemorrhage. In younger people (<60 years) the commonest cause is reversible cerebral vasoconstriction syndrome (RCVS), typically presenting with recurrent thunderclap headaches^{5,6}. Other, much less common, causes of cSAH include posterior reversible encephalopathy syndrome (PRES), cerebral venous thrombosis (CVT), infections (e.g. endocarditis), coagulopathies (e.g. disseminated intravascular coagulation) and Moya Moya syndrome. Unlike other patterns of SAH, cSAH is hardly ever due to an underlying macrovascular pathology such as a ruptured aneurysm, arterio-venous-malformation (AVM), or tumor^{5,6}.

The sensitivity of unenhanced CT is very high in diagnosing acute cSAH and is usually the first investigation⁷. cSAH can also be readily detected on MRI FLAIR sequences. Over time cSAH evolves into cortical superficial siderosis (cSS) due to deposition of hemosiderin (generated by blood breakdown) in subpial cortical layers; gradient-recalled echo and susceptibility-weighted images can therefore detect evidence of prior episodes of cSAH as sulcal hemosiderin or cSS (Figure 1)⁵.

Convexity SAH has received limited attention from neurosurgeons, perhaps because of the low yield of macrovascular causes and a perceived benign prognosis. Patients with cSAH might therefore not be routinely followed-up and are usually considered of interest mainly for neurologists. But is this really true? In recent years it has become clear that cSAH has distinct and readily recognized causes, which do not always have a benign course.

RCVS is the most likely etiology in patients under the age of 60⁸. Multifocal and synchronous cSAH can be seen in RCVS, a feature that is not typical of CAA. RCVS typically presents with thunderclap headache identical to that seen in aneurysmal SAH: the key distinction is that in RCVS headaches are usually recurrent, a feature said to be almost diagnostic of this entity⁶. Nevertheless, patients with RCVS are often referred directly to neurosurgeons from the emergency department. Although cerebral vasculitis is considered when either noninvasive or catheter angiography shows the radiological appearance of multiple areas of arterial caliber abnormality, in our experience the clinical picture of recurrent thunderclap headache is highly suggestive of RCVS and should help clinicians to avoid unnecessary tests for cerebral vasculitis (e.g. lumbar puncture or cerebral biopsy).

In patients over the age of 60, cSAH is frequently associated with imaging markers of CAA⁴, an age-related process of accumulation of amyloid-beta in superficial leptomenigeal and cortical arterioles near the brain's cortical surface. In CAA, cSAH results from bleeding into the subarachnoid space from abnormally fragile amyloid-laden vessels⁹. The typical clinical presentation is with TFNE, typically stereotyped recurrent attacks of sensory or motor disturbance (numbness, tingling, weakness) affecting face, arm or leg but without thunderclap headache (unlike typical aneurysmal SAH)¹⁰; a less severe or gradual onset headache can occur. Such patients might therefore present to TIA clinics or emergency departments before referral to neurosurgery. In cSAH due to probable CAA it is increasingly recognized that the course might not be as favorable as previously believed¹¹, with a high risk of future symptomatic ICH of up to 19% per patient-year in patients fulfilling the Boston criteria for probable CAA^{11,12}. Gold-standard for CAA diagnosis is neuropathological confirmation, but the modified Boston criteria have emerged as a reasonable tool instead. They include CMB and cSS to noninvasively diagnose CAA with good diagnostic accuracy¹³: Therefore, once a diagnosis of SAH is confirmed, the next most useful diagnostic tool for CAA is MRI with blood-sensitive sequences to detect biomarkers of CAA. Probable CAA (with highest diagnostic certainty) is diagnosed with the following criteria: age ≥ 55 years; multiple ICH restricted to lobar, cortical or corticosubcortical regions or single lobar, cortical or corticosubcortical ICH in addition to focal or disseminated SS; with no other underlying cause present.

DSA is rarely required in patients with cSAH if clinical and radiological features are supportive of either RCVS or CAA (Figure 2) but remains essential in cases of diagnostic uncertainty.

The treatment of cSAH depends on the cause. In RCVS, nimodipine is often used, and might reduce frequency and severity of thunderclap headaches though controlled trials are not available¹⁴. Steroids do not seem to be helpful and might even be harmful¹⁵. A careful search for known precipitating factors (e.g. sympathomimetic drugs, SSRIs, etc.) is important and patients should be advised to avoid any triggers identified. For cSAH due to CAA, typically TFNE recur over a short time period¹⁶. These attacks seem to respond to both anticonvulsant drugs (e.g. levetiracetam) or migraine preventives (e.g. topiramate)¹⁷, though there are no controlled trials. Patients should be reassured that although these attacks may be distressing, each attack does not usually reflect new bleeding, and the natural history is usually of improvement and remission over days to weeks. There are no interventions proven to reduce ICH or recurrent cSAH risk. However, extrapolating data from patients with CAA presenting with ICH, blood pressure reduction to a target of 130/80 is reasonable, as well as avoiding exposure to antithrombotic (antiplatelet and anticoagulant) drugs wherever possible.

Further research is needed to understand the underlying pathophysiology of cSAH in both RCVS and CAA, which should allow rational treatments proven to reduce complications and improve outcomes in both of these conditions. In the meantime, neurosurgeons should be aware of the highly characteristic clinical-radiological syndromes associated with cSAH because these require a different approach to investigation to the more common aneurysmal form of nontraumatic SAH.

REFERENCES

1. Khurram A, Kleinig T, Leyden J. Clinical associations and causes of convexity subarachnoid hemorrhage. *Stroke; a journal of cerebral circulation*. 2014;45(4):1151-1153.
2. Beitzke M, Gattringer T, Enzinger C, Wagner G, Niederkorn K, Fazekas F. Clinical presentation, etiology, and long-term prognosis in patients with nontraumatic convexal subarachnoid hemorrhage. *Stroke; a journal of cerebral circulation*. 2011;42(11):3055-3060.
3. Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. *Stroke; a journal of cerebral circulation*. 2010;41(11):2505-2511.
4. Raposo N, Viguier A, Cuvinciu V, et al. Cortical subarachnoid haemorrhage in the elderly: a recurrent event probably related to cerebral amyloid angiopathy. *European journal of neurology*. 2011;18(4):597-603.
5. Mangla R, Drumsta D, Alamst J, Mangla M, Potchen M. Cerebral convexity subarachnoid hemorrhage: various causes and role of diagnostic imaging. *Emergency radiology*. 2015;22(2):181-195.
6. Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. *Brain : a journal of neurology*. 2007;130(Pt 12):3091-3101.
7. Refai D, Botros JA, Strom RG, Derdeyn CP, Sharma A, Zipfel GJ. Spontaneous isolated convexity subarachnoid hemorrhage: presentation, radiological findings, differential diagnosis, and clinical course. *Journal of neurosurgery*. 2008;109(6):1034-1041.
8. Kumar S, Goddeau RP, Jr., Selim MH, et al. Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies. *Neurology*. 2010;74(11):893-899.
9. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. *Journal of neurology, neurosurgery, and psychiatry*. 2012;83(2):124-137.
10. Charidimou A, Peeters A, Fox Z, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. *Stroke; a journal of cerebral circulation*. 2012;43(9):2324-2330.
11. Wilson D, Hostettler IC, Ambler G, Banerjee G, Jager HR, Werring DJ. Convexity subarachnoid haemorrhage has a high risk of intracerebral haemorrhage in suspected cerebral amyloid angiopathy. *Journal of neurology*. 2017.
12. van Etten ES, Auriel E, Haley KE, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. *Stroke; a journal of cerebral circulation*. 2014;45(8):2280-2285.
13. Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology*. 2010;74(17):1346-1350.
14. Zuber M, Touze E, Domingo V, Trystram D, Lamy C, Mas JL. Reversible cerebral angiopathy: efficacy of nimodipine. *Journal of neurology*. 2006;253(12):1585-1588.
15. Ducros A. Reversible cerebral vasoconstriction syndrome. *The Lancet Neurology*. 2012;11(10):906-917.
16. Charidimou A, Baron JC, Werring DJ. Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs. *International journal of stroke : official journal of the International Stroke Society*. 2013;8(2):105-108.
17. Roch JA, Nighoghossian N, Hermier M, et al. Transient neurologic symptoms related to cerebral amyloid angiopathy: usefulness of T2*-weighted imaging. *Cerebrovascular diseases*. 2005;20(5):412-414.

FIGURE LEGEND

Figure 1. Axial images of 3 patients with cSAH: A) CT scan showing acute cSAH in a patient with left sided migratory sensory symptoms; B) susceptibility-weighted image (SWI) of the same patient 11 days after the acute cSAH clearly showing sulcal hemosiderin and evolving cSS in the areas of previous cSAH; C) CT scan of a patient 3 days after presentation with thunderclap headache; D) SWI image of the same patient 6 months after the acute cSAH, showing cSS in the areas of previous cSAH; E) T2*-weighted gradient-recalled echo (GRE) who three years earlier had cSAH associated with clumsiness and tingling of the left hand, showing typical disseminated cSS; F) CT scan of the same patient who went on to develop an ICH 3 months after the MR scan shown in panel E).

Figure 2. Suggested diagnostic pathway for acute, nontraumatic cSAH.

